Latest Heart Device – Subcutaneous Implantable Defibrillator (S-ICD System) – Continues To Show Positive Results

New data from the international EFFORTLESS S-ICD Registry presented at Heart Rhythm 2012 shows the S-ICD System as a viable option for most ICD patients

May 10, 2012

Media Contact

Shane Osborne
Heart Rhythm Society
media@hrsonline.org
202-464-3431

BOSTON, May 10, 2012 – Initial results from the international Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS (EFFORTLESS) subcutaneous implantable defibrillator (S-ICD System) Registry shows that the latest heart device, the S-ICD System, is performing appropriately in real-world circumstances and continues to show positive results in patients. Data analyzed from the largest study of real world experience using the S-ICD System to-date, demonstrated a conversion rate >98% for induced and ambulatory ventricular tachycardia or fibrillation (VT/VF), consistent with transvenous ICD systems.  This data is being presented for the first time today at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions. View the International Experience with a Subcutaneous ICD; Preliminary Results of the EFFORTLESS S-ICD Registry abstract.
 
The purpose of an ICD is to convert all episodes of VT/VF through a defibrillation shock to the heart.  The S-ICD System is a new generation of the ICD that does not require intravascular leads.  Instead, the S-ICD System electrode is inserted under the skin and outside of the ribcage.  The S-ICD System is an alternative for most patients requiring protection from sudden cardiac arrest (SCA).  However, the S-ICD System is not intended for those patients having bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.

The EFFORTLESS registry was designed to evaluate the long-term performance of the S-ICD System, including, patient quality of life and long-term resource utilization.  The registry is an observational, non-randomized, standard of care evaluation collecting data at international investigational centers where the S-ICD System is approved for use and distribution.

Data from 230 patients that received an S-ICD System at clinical centers in nine countries, including the United Kingdom, Netherlands, Czech Republic, Slovakia, Denmark, Italy, Germany, Portugal and New Zealand, were reviewed and showed:

  • 64 percent were for primary prevention (of which 49 percent were ischemic).
  • Ischemic indications accounted for 38 percent of all patients implanted
  • Channelopathies (including Brugada syndrome; Long-QT syndrome and CPVT) accounted for 13 percent of all patients implanted
  • 28 patients received ambulatory shock therapy (13 percent; n=72 episodes):
    • 48 spontaneous VT/VF episodes were all appropriately converted
    • Annual inappropriate shock rate was seven percent
  • Induced shock conversion efficacy within one procedure was 98.5 percent with an average time to therapy for the first shock of 16±4 seconds.
  • No patient received therapy for any SVTs (including atrial fibrillation) within a programmed conditional shock zone.

“This data shows us that the S-ICD System is proving to be safe and effective and possibly even a slightly better option than a regular ICD for certain patients,” said Pier D. Lambiase, MD, PhD, FRCP, lead author and senior lecturer and honorary consultant cardiologist at Heart Hospital, University College of London. “Our goal is to provide patients with heart devices that are less invasive, yet perform the same or better than other options. Real-world data is critical for us to understand therapy outcomes and so far we are very impressed with the performance of the S-ICD System in a wide range of patients.”

On April 26, 2012, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel recommended approval of Cameron Health’s S-ICD System.  This recommendation was a result of a 7-1 panel vote in favor of sufficient data demonstrating the efficacy and safety of the S-ICD System for the treatment of SCA.  

The S-ICD System was introduced in Europe in 2009 and results from the first 98 patients were presented at Heart Rhythm 2011, see information here .

Sessions details:

“International Experience with a subcutaneous ICD: Preliminary results of the EFFORTLESS S-ICD Registry” [Thursday, May 10, 2012, 1:30 p.m. – 3:00 p.m. EDT, Room 154]

Heart Rhythm 2012 is the most comprehensive educational program for heart rhythm professionals, featuring more than 250 educational sections and more than 130 innovative products and services.  The Heart Rhythm Society’s Annual Scientific Sessions have become the must-attend event of the year, allowing the exchange of new vital ideas and information among colleagues from every corner of the globe.

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 5,900 heart rhythm professionals in more than 70 countries around the world. For more information, visit www.HRSonline.org .